A pill in development for sleep apnea: what Apnimed’s sulthiame move really means

Apnimed, a company focused on drug treatments for sleep-related breathing problems, has acquired the global rights to develop sulthiame for obstructive sleep apnea (OSA). If you’ve never heard of sulthiame, you’re not alone. It’s an older medicine used outside the U.S. for other conditions, now being repurposed to steady breathing during sleep. The plan is to develop it within Apnimed’s joint venture with Shionogi (called SASS), alongside Apnimed’s lead OSA pill, AD109. Each works in a different way, which matters for a condition as mixed and messy as sleep apnea. What makes sulthiame interesting is its target. It’s a carbonic anhydrase inhibitor, a class that can shift the body’s chemistry just enough to make breathing more stable at night. In sleep apnea, some people have “high loop gain,” meaning their breathing control system overreacts to small changes and gets stuck in a stop-start cycle. Early trials in Europe suggest sulthiame can lower that tendency and make the upper airway less likely to collapse. In a four- to twelve-week program that enrolled roughly 300 adults with OSA who weren’t using CPAP, sulthiame cut apnea events and improved oxygen levels compared with placebo. Researchers also reported changes in physiological markers that point to steadier overnight breathing. These studies are short and need to be reproduced, but they explain why a repurposed drug is suddenly on center stage. Apnimed’s deal is not just about one drug. The company is also running phase 3 trials of AD109, a once-nightly combo pill (atomoxetine plus aroxybutynin) that aims to stiffen the muscles around the airway so it stays open. Sulthiame takes a different route by calming the control system behind breathing. If both approaches pan out, doctors could one day match people to the mechanism that suits them, or even combine tools for tougher cases. That’s the strategic logic behind putting sulthiame into the SASS joint venture with Shionogi. A few reality checks. Sulthiame is not approved in the U.S. for any use today, and the OSA data so far are phase 2 and mostly European. The press material describes a favorable safety profile to date, but larger, longer studies are still required to understand who benefits, how durable the effect is, and how the medicine fits with existing options like CPAP, oral appliances, weight-loss drugs or surgery. Apnimed’s announcement moves the program forward; it doesn’t make sulthiame available at your pharmacy. So what should people with sleep apnea take from this? First, drug therapy for OSA is gaining momentum after years dominated by devices. Second, different biological “end types” of OSA likely need different tools; a stabilizer like sulthiame won’t be the answer for everyone, just as a muscle-tone drug like AD109 won’t either. Third, if you’re curious about medication options, talk with your clinician about clinical trials near you, especially as Apnimed and partners expand testing. For now, the headline is simple: a repurposed pill with encouraging mid-stage data has a serious developer behind it and a clear path into broader studies. That’s progress, even if it’s not a cure-all.